Table 5.
Plant-derived vaccines and their clinical trial phase.
| Target | Interventions? | Plant Host | Study Type | Study Completion Date | Sponsor |
|---|---|---|---|---|---|
| Malaria | Pfs25 VLP- FhCMB | N. benthamiana | Interventional (Clinical Trial: Phase 1) (NCT02013687) | January 2015 | Fraunhofer, Center for Molecular Biotechnology |
| Anthrax | PA83-FhCMB | N. benthamiana | Interventional (Clinical Trial: Phase 1) (NCT02239172) | May 2015 | Fraunhofer, Center for Molecular Biotechnology |
| Influenza A Subtype H5N1 Infection | H5-VLP + GLA-AF; Licensed H5N1 vaccine | N. benthamiana | Interventional (Clinical Trial: Phase 1) (NCT01657929) | January 2014 | IDRI |
| H5N1 Flu | HAI-05 Influenza Vaccine; Saline | N. benthamiana | Interventional (Clinical Trial: Phase 1) (NCT01250795) | July 2011 | Fraunhofer, Center for Molecular Biotechnology |
| 2018−2019 influenza season | Quadrivalent VLP Vaccine | N. benthamiana | Interventional (Clinical Trial: Phase 3) (NCT03739112) | June 14, 2019 | Medicago |
| H1N1 Flu | HAC1 Vaccine | N. benthamiana | Interventional (Clinical Trial: Phase 1) (NCT01177202) | October 2012 | Fraunhofer, Center for Molecular Biotechnology |
| H1N1 Flu | Quadrivalent VLP Vaccine; Placebo | N. benthamiana | Interventional (Clinical Trial: Phase 3) (NCT03301051) | June 2018 | Medicago |
| H1N1 Flu | H1N1 VLP vaccine | N. benthamiana | Interventional (Clinical Trial; phas 1) (NCT01302990) | July 2011 | Medicago |
| H5N1 Flu | H5N1 VLP vaccine | N. benthamiana | Interventional (Clinical Trial; Phase 2) (NCT01991561) | July 2014 | Medicago |
| H7N9 Flu | H7N9 VLP vaccine | N. benthamiana | Interventional (Clinical Trial; Phase 1) (NCT02022163) | September 2014 | Medicago |
| Lymphoma, Follicular | Autologous FL vaccine | N. benthamiana | Interventional (Clinical Trial; Phase 1) (NCT01022255) | October 2013 | Icon Genetics GmbH |
| HIV Infection | P2G12 | N. tabacum | Interventional (Clinical Trial; Phase 1) (NCT02923999) | August 2020 | St George's, University of London |